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PREVALENCE OF PCOS DIAGNOSES AMONG WOMEN WITH MENSTRUAL 
IRREGULARITY IN A DIVERSE, MULTIETHNIC COHORT 
RASHMI MADHAVAN 
ABSTRACT 
Objective: To examine the likelihood of self-reporting a diagnosis for PCOS with the 
presentation of menstrual irregularity in a diverse, multiethnic population, based on data 
collected between August 9th, 2017 and October 24th, 2017 for the pilot of the Ovulation 
and Menstruation (OM) Study at Boston University School of Medicine. 
Background: Polycystic ovary syndrome, or PCOS, is the most common endocrine 
disorder among reproductive age women. It is typically diagnosed by variable 
combinations of menstrual irregularity, clinical or biochemical hyperandrogenism, and 
polycystic ovaries on ultrasound. An alternative is its diagnosis as one of exclusion due to 
similarities in presentation to other endocrine disorders. As a result, PCOS may often be 
misdiagnosed and mismanaged in the course of a patient’s care, further exacerbated by a 
poor understanding of the syndrome, a lack of easily available resources, and patient 
frustration with clinician interactions. The early identification of key hallmarks of the 
disorder, such as menstrual irregularity, and awareness of its linkage to PCOS, could lead 
to early diagnosis and intervention. 
Methods: 248 participants enrolled and participated in the Ovulation and Menstruation 
(OM) Health Study’s as members of its pilot cohort. Inclusion criteria were women ages 
18-45 currently experiencing menstrual periods without a history of chemotherapy, 
radiation, or surgical menopause. Participants completed the relevant sections of the OM 
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Study survey related to demographics, menstrual cycle patterns, and history of PCOS. 
Demographic questions pertained to the age, race/ethnicity, country of birth, and 
education levels of the participants. The menstrual cycle questions provided information 
regarding the age of menarche, length and pattern of menses and the menstrual cycle 
overall. The questions regarding history of PCOS ascertained the presence of an official 
or self-diagnosis for PCOS for the participant, and the age at which this was determined. 
The descriptive measures were presented for comparison before determining the 
concurrence of the presence of menstrual irregularity and the diagnosis of PCOS across 
demographic categories and calculating an associated prevalence ratio.  
Results: Among women reporting a history of menstrual irregularity for 3 months or 
greater, PCOS was the second-highest self-reported cause for menstrual irregularity, with 
20.7% of participants endorsing it as the cause for their irregularity. The presence of 
menstrual irregularity for 3 or more months was also more likely to be present in 
concurrence with a clinician diagnosis, or to a lesser extent, a self-diagnosis, for PCOS. 
Participants were also far more likely to have a clinician diagnosis for PCOS if they were 
White, US-born, young, or educated. The same applied for the likelihood of a self-
diagnosis with the exception of age.  
Conclusions: The association between menstrual cycle irregularities and likelihood of 
being diagnosed with PCOS is supported by the data and appears to be influenced by 
demographic factors such as race/ethnicity, age, and education.  
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INTRODUCTION 
 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder 
among women of reproductive age, affecting approximately 6-10% of this group, though 
it can be up to 15% when the Rotterdam criteria for diagnosis is applied (Sills et al., 
2001; Fauser et al., 2012; Engmann & Legro, 2013). The disorder was originally 
established by Dr. Irving Stein and Dr. Michael Leventhal, who evaluated women with 
complaints of amenorrhea, excess hair growth, and/or pelvic pain with transabdominal 
pneumography to note bilaterally enlarged cystic ovaries. Further clinical investigation of 
the cystic ovaries with ovarian wedge resection eventually led to the identification and 
establishment of the disorder as polycystic ovary syndrome, or PCOS (Stein & Leventhal, 
1935; Azziz & Adashi, 2016).  
PCOS is the most common cause of infertility in adult women due to 
anovulation/oligoovulation (Bani Mohammad, M. & Majdi Seghinsara, A. 2017). Other 
common symptoms related to PCOS include hirsutism and other symptoms of 
androgenization. PCOS is also significantly associated with many other clinically 
concerning diagnoses. A high incidence of PCOS has been identified in patients with 
obesity, type II diabetes, impaired glucose tolerance, insulin resistance, and metabolic 
syndrome (El Hayek, Bitar, Hamdar, Mirza, & Daoud, 2016). Adults females with PCOS 
have also been shown to be at a greater risk for endometrial cancer and infertility. 
Additionally, the disorder has a very similar presentation to many other disorders, 
including congenital adrenal hyperplasia, Cushing’s syndrome, androgen-secreting 
tumors, and hypogonadotropic hypogonadism (The Rotterdam ESHRE/ASRM-sponsored 
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PCOS consensus workshop group, 2004). Therefore, PCOS is generally considered a 
diagnosis of exclusion, and it is recommended that clinicians first rule out any other 
etiologies for the patient’s symptoms (Pasquali & Gambineri, 2015). 
Several decades since its discovery, there is still significant uncertainty regarding 
the etiology, presentation, and pathogenesis of PCOS (Bani Mohammad, M. & Majdi 
Seghinsara, A. 2017). One suggested evolutionary mechanism for the disorder’s 
persistence over time is the facilitation of small family sizes, reduced exposure to 
childbirth-related mortality, increased muscle mass, and allowing a greater capacity to 
store energy (Goodarzi, Dumesic, Chazenbalk, & Azziz, 2011). The heterogeneity in 
associated presentations is thought to be adjusted by genetic and environmental factors 
(Bani Mohammad, M. & Majdi Seghinsara, A. 2017). Overall, the disease presents a 
physical, psychological, emotional, and economic burden on both adults and adolescents, 
with over $4 billion spent annually to explore new diagnostic screening methods and 
treatment for all its symptoms and comorbidities (El Hayek et al., 2016). 
 
1. Diagnostic Criteria for PCOS  
Currently, three primary guidelines exist to identify PCOS among its constellation of 
associated symptoms. The first set of criteria was established in 1990 during an 
international conference on PCOS sponsored by the NIH. Formulated by majority 
opinion with limited consensus more than clinical evidence, the NIH criteria defined 
PCOS as chronic anovulation, hyperandrogenism that presented as hirsutism or other 
clinical or biochemical features, and exclusion of any other etiologies (The Rotterdam 
ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004). This set of criteria 
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placed particular emphasis on the presentation of hyperandrogenism, due to its relation to 
hyperinsulinemia and subsequent associated metabolic dysfunction in PCOS individuals 
(Goodarzi et al., 2011). 
As more evidence regarding the broad heterogeneity of PCOS symptoms was brought 
to light, another conference was held in the Netherlands to revise the diagnostic criteria 
for the disorder, sponsored by the European Society for Human Reproduction and 
Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRE). 
The eponymous Rotterdam criteria provided more flexibility in the identification of 
PCOS and included evaluation of two out of three of the following symptoms: menstrual 
irregularity, clinical or biochemical evidence of hyperandrogenism, and/or presence of 
multiple ovarian cysts as confirmed via transabdominal or transvaginal ultrasound, with 
exclusion of all other etiologies (The Rotterdam ESHRE/ASRM-sponsored PCOS 
consensus workshop group, 2004; El Hayek et al., 2016). This set of criteria was proven 
useful in accounting for the ethnic variation in the presentation of hyperandrogenism, 
such as with the minimal hirsutism in Asian women (Goodarzi et al., 2011) 
A third set of criteria was also established in recent years by a task force of experts 
established by the Androgen Excess Society in 2006 (Azziz et al., 2006). In contrast to 
previous criteria, the task force sought to define PCOS as a predominantly 
hyperandrogenic syndrome (Azziz et al., 2006). Based on the key features of PCOS 
determined by the existing data, the AES guidelines identified the following as the 
suggested criteria for diagnosis: 1) hyperandrogenism (biological or clinical) and 2) 
ovulatory dysfunction (either oligo-anovulation or polycystic ovaries). This criteria, 
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much like the NIH guidelines from before, also sought to highlight the hyperandrogenic 
nature of the disorder, with particular emphasis on the phenotypic presentation of related 
symptoms such as hirsutism that might be indicative of underlying metabolic concerns 
and ultimately prove to be of future clinical concern (Azziz et al., 2009).  
 
Figure 1. Summary of Diagnostic Criteria for PCOS (El Hayek et al, 2016). 
 
 
2. Manifestations and Consequences 
a. Reproductive Consequences    
Irregular menstruation is the most common phenotype among PCOS women, with 
95% of women with PCOS experiencing either oligomenorrhea (less than eight menstrual 
periods per year) or amenorrhea (Barthelmess & Naz, 2014). In adolescents, the 
presentation of menstrual irregularity in the post-menarchal years was originally thought 
to be expected due to the maturing of the hypothalamic-pituitary-ovarian (HPO) axis. 
However, recent research indicates that the menstrual patterns during these years may be 
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predictive of diseases relating to disorders of the axis, including IR (da Silva Bouzas, 
Cader, Leão, Kuschnir, & Braga, 2014). Infertility is another consequence experienced by 
women with PCOS. As many as 20% of women with fertility complications have been 
diagnosed with PCOS (Barthelmess & Naz, 2014). It is primarily caused by the 
anovulation that is associated with PCOS (Goodarzi et al 2011). Women diagnosed with 
PCOS who are able to conceive are still at a greater risk for many conditions during 
pregnancy, including gestational diabetes, pregnancy-induced hypertension, 
preeclampsia, and pre-term birth (Setji & Brown, 2014). There is also a three-fold greater 
risk of developing endometrial cancer in women who have PCOS (El Hayek et al., 2016; 
Fauser et al., 2012). Anovulation triggers unopposed estrogen exposure in the uterus, 
consequently leading to endometrial hyperplasia (El Hayek et al., 2016).  
b. Metabolic Consequences  
  There is a strong association between PCOS and insulin resistance. Individuals 
with PCOS develop alterations in their glucose metabolism, with impaired glucose 
tolerance and type II diabetes being the most common presentations (Pasquali & 
Gambineri, 2015). Menstrual irregularities present in the setting of hyperinsulinemia 
could also be caused by the alteration of the GnRH pulse secretion patterns, suppressing 
SHBG and stimulating ovarian androgenesis (da Silva Bouzas et al., 2014) 
 Obesity is also considered one of the most significant comorbidities of PCOS, 
with a prevalence of 61-76% among women with the disorder globally, and up to 80% in 
just the US (El Hayek et al., 2016). Randeva et al. (2012) identified that the increased 
androgen production rates in PCOS women put them at a higher risk of increased visceral 
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and subcutaneous fat depositions, leading to the development of obesity. Additionally, 
just as IR is associated with a higher risk of developing obesity, obese women are also at 
a higher risk of developing IR, as well as metabolic syndrome and PCOS later in life (El 
Hayek et al., 2016). The connection between obesity and PCOS may affect women as 
early as adolescence, at which time an early increase in body weight could be indicative 
of testosterone excess and may be related to any menses irregularities present at the time.  
 The presence of clinically identifiable hyperandrogenism is another marked 
feature of the PCOS phenotype. The primary feature of hyperandrogenism is hirsutism, 
the presence of excess body hair growth. The most common visual standard for the 
evaluation of hirsutism is the Ferriman-Gallwey score, which allows easy, convenient, 
and fast assessment of body hair growth based on a ranking of 0-4 of 9 major body 
regions (Yildiz, Bolour, Woods, Moore, & Azziz, 2010). Alopecia, or scalp hair loss, as 
well as acne can also be considered a by-product of elevated androgen levels, but are 
generally considered poor markers of clinical hyperandrogenism by themselves (The 
Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004).  
 To further complicate matters, the PCOS phenotypes also change dramatically 
across age, both clinically and endocrinologically, with menstrual cycles becoming more 
regular and both androgen levels and insulin resistance typically diminishing over time 
(Pasquali & Gambineri, 2015). Nevertheless, early identification of these symptoms can 
allow for appropriate management techniques to be implemented to combat their effect 
early on through medical treatment and lifestyle adjustments.  
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3. Barriers to Receiving a Diagnosis  
Despite the establishment of multiple diagnostic criteria, the rate of 
underdiagnoses compared to prevalence of PCOS in the community is significant. In the 
first community-based study of PCOS, there was a 18% prevalence of PCOS, with 70% 
of the women having been underdiagnosed, suggesting a strong deficiency in adequate 
recognition and treatment for this condition (Sills et al., 2001). The issues related to 
misdiagnosis and underdiagnosis can be addressed as a two-fold problem – a lack of 
understanding and familiarity on the clinician side, and a widespread confusion and 
frustration on the patient side.  
Clinicians and PCOS  
One of the primary issues preventing consistent diagnosis of PCOS among 
women of reproductive age is the persisting poor understanding of the disorder among 
clinicians. Even the name “polycystic ovary syndrome” is starting to be considered a 
misnomer on its own - cysts themselves are typically epithelium-lined fluid-filled sacs 
greater than 2 cm, while the atretic ovarian follicles associated with PCOS are typically 
less than 8 mm and not lined by an epithelium (Teede, Gibson-Helm, Norman, & Boyle, 
2014). Going even further, polycystic ovaries are not even necessary to prompt a 
potential diagnosis for PCOS, as delineated by the more recent Rotterdam and AES 
criteria.  
The lack of familiarity also contributes to the poor identification of the disorder in 
patients. PCOS is considered a diagnosis of exclusion – multiple other differential 
diagnoses for amenorrhea and hyperandrogenism must be ruled out in the medical 
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decision-making, including hypothyroidism, hyperprolactinemia, congenital adrenal 
hyperplasia, menopause, and rarely, androgen-secreting tumors and Cushing’s syndrome 
(Teede et al., 2014). The presentation of PCOS has been acknowledged to have multiple 
heterogeneous presentations that also vary across age and race/ethnicity and indicative of 
several other comorbidities (March et al., 2010; Dokras et al., 2017). While physicians 
have generally reported being familiar with the most commonly known comorbidities, 
including obesity, diabetes, insulin resistance, and depression, they are less likely to 
know associations between PCOS and conditions such as sleep apnea, fatty liver, 
endometrial cancer, gestational diabetes, and anxiety (Dokras et al., 2017). With such a 
diverse presentation, the diagnosis of PCOS may necessarily involve evaluation by 
multiple different providers, and the lack of coordination of care between these 
physicians may result in the lack of the kind of comprehensive assessment necessary for 
the diagnosis of PCOS (Gibson-Helm, Teede, Dunaif, & Dokras, 2017).  
Furthermore, while the various diagnostic criteria have provided more concrete 
guidelines for identifying PCOS in women, the actual implementation of these 
parameters in the clinical setting have had their own challenges. According to a study by 
Dokras et al. (2017), only 68.3% of REI specialists and 41.2% of OB/GYNs report using 
the clinically recommended Rotterdam criteria to purposefully diagnose patients with 
PCOS. The requirement of diagnostic ultrasounds and/or blood tests, which cannot 
always be done in a PCP or OB/GYN’s office, have also delayed the proper adoption of 
the PCOS diagnostic criteria and confirmatory diagnosis of PCOS by physicians (March 
et al., 2010; Dokras et al., 2017). Additionally, the definitions for clinical and 
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biochemical hyperandrogenism have not been standardized and are often determined far 
too subjectively (Dokras et al., 2017).  
Current literature also suggests that the problem of underdiagnoses is particularly 
exacerbated in adolescents due to the concurrent prevalence of certain PCOS indicators in 
the teenage years. Some of the primary indicators of PCOS, including anovulation, cyst 
development, presence of multiple follicles, and acne, are also commonly present in the 
normal progression of puberty (Bani Mohammad, M. & Majdi Seghinsara, A. 2017). As a 
result, healthcare providers are less likely to be concerned about such symptoms or 
pursue further investigation at that age, and instead control symptoms using oral 
contraception (Tomlinson et al., 2017). Due to such minimal management, however, 
there is a possibility for further issues with PCOS and infertility in the future. 
Patients and PCOS 
On the patient end of the issue, seeking a diagnosis for PCOS-related concerns is 
a process plagued by frustration, confusion, and helplessness. Gibson-Helm et al. (2017) 
conducted a study on the overall patient satisfaction with their PCOS diagnosis 
experience to find that only 35.2% of their patient sample were satisfied with their 
journey to an official diagnosis, based on variables that included the time to diagnosis 
since initially seeking care, the number of healthcare professionals seen to attain a 
diagnosis, and the satisfaction with the information they received from their healthcare 
provide.  
One of the main reasons patient satisfaction with the diagnostic process for PCOS 
is so low is due to frustration with clinical providers.  Patients have reported numerous 
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concerns in their relationship with healthcare professionals in trying to receive an answer 
regarding their symptomatology. Tomlinson et al. (2017) identify a wide variety of issues 
that women have reported as obstacles in communicating their condition and related 
concerns to clinicians, including a lack of empathy from healthcare professionals 
(particularly when presenting with weight gain), difficulty in accessing specialist referrals 
or more accurate information with regard to PCOS and related infertility issues, and a 
lack of education about the long-term risks of living with PCOS.  
 The negative patient experience of receiving a diagnosis is further exacerbated by 
the substantial confusion patients are often left with regarding their condition. Often 
times, patients have to dedicate a lot of time to undergoing multiple tests and visiting 
multiple specialists to even get their symptoms taken seriously enough to merit 
investigation, much less an actual diagnosis (Crete & Adamshick, 2011). This often leads 
to patients striking out on their own to find their own sources of information to 
understand their condition, leading to a lot of self-diagnosis and management of PCOS 
(Crete & Adamshick, 2011). Patients report that they sometimes have to be the ones to 
push physicians to do certain diagnostic testing in order to convince them that their 
symptoms are real (Williams, Sheffield, & Knibb, 2015).  
4. The Intersection Between Demographics, Menstrual Irregularity, and PCOS 
Menstrual Irregularity Across Demographic Categories 
 The influence of race/ethnicity on menstrual regularity is an area with conflicting 
research. Engmann & Legro, (2013) report that the prevalence of menstrual irregularity in 
current literature ranges from 4.4% in a Swedish population up to 21% among Pima 
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Indians, with no significant difference between White and Black populations. The most 
pronounced racial/ethnic differences in menstruation are primarily at menarche, which 
was reached, on average, earliest by Black girls, then Hispanic, then White, independent 
of any socioeconomic factors, though a higher BMI and lower energy intake are linked to 
earlier menarche (Wu, Mendola, & Buck, 2002; Chumlea et al., 2003). These differences 
were also noted by Deardorff et al (2014), though adjustment for SES factors, including 
mother’s unmarried status and lower family income, did reduce the effect of 
race/ethnicity by 40% for Black girls and 50% for Hispanic girls. Black girls were noted 
to reach menarche at an average of 2-3 months before White girls, and even with 
adjustment for weight, height, and skinfold thickness, the rate of early menarche was 1.4-
fold higher in Black girls than in White girls (Freedman et al., 2002).  Differences were 
also pronounced in the early post-menarchal period, with White girls having a 
significantly higher probability of having an extreme cycle length (defined as cycles 
longer than 45 days), a slightly longer mean cycle length, and more in-group variance 
compared to Black girls, possibly attributed to higher activity levels and lower 
weight/height ratio (Harlow, Campbell, Lin, & Raz, 1997). Post-menarchal Black girls 
are also more likely to report episodes of heavier bleeding despite shorter cycle lengths 
by about half a day compared to White girls, though weight and diet are influencing 
factors (Harlow et al., 1997). Overall, the differences in menstrual cycle characteristics 
between various race/ethnicity groups are significant as early as menarche, as they may 
be indicative of differences that persist later in reproductive life, as well as differences in 
long-term risk of chronic disease ((Harlow et al., 1997).  
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 Age is also a significant factor in considering menstrual cycle regularity. It is 
well-established that menstrual irregularity is higher in prevalence in menarchal women 
compared to perimenopausal women, due to the menstrual cycle generally normalizing 
over time (Dimitrios Panidis et al., 2015) . Additionally, the more severe cycle 
abnormalities tend to decrease in prevalence over time, while milder cycle abnormalities 
increase with age (Dimitrios Panidis et al., 2015). A woman’s age also influences how 
she tends to track her own menstrual cycle, with women between the ages 30 and 34 up 
to three times more likely to accurately report within 2 days of actual cycle length 
compared to women younger than 25 (Small, Manatunga, & Marcus, 2007).  
 In general, understanding the differences in menstrual cycle regularity across 
various age and racial/ethnic groups may allow for a more comprehensive understanding 
of abnormalities in various populations and for the early identification of potential 
menstrual dysfunction (Harlow et al., 1997). 
Diagnosis of PCOS Across Demographic Categories 
 The diagnosis of PCOS may be subject to a high degree of variability in the 
presentation of the disorder across demographic categories, such as race/ethnicity. The 
majority of the early research done on women with PCOS was conducted primarily with 
White participants, limiting the understanding of how race and ethnicity might affect the 
presentation of the syndrome (Knochenhauer et al., 1998). The variability of PCOS 
across racial/ethnic groups have primarily been analyzed based on the variations in the 
presentation of the PCOS phenotype, which in turn affects how the syndrome is 
diagnosed. A summary of the major findings in the literature are shown in Table 1.  
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Table 1. Summary of PCOS presentation across racial/ethnic categories.  
Race Reproductive Profile Metabolic Profile 
Black PCOS-associated 
reproductive profiles do 
not differ greatly from 
White women  
Milder phenotype than Hispanic 
women when associated with PCOS 
Hispanic – 
Mexican 
American and 
Caribbean 
Highest prevalence of 
PCO morphology in one 
or both ovaries 
compared to White and 
Black women 
Markedly higher rates of IR, 
hyperinsulinemia, type II diabetes, and 
obesity (Caribbean tends to be even 
higher than Mexican Americans) 
East Asian N/A Low testosterone levels, BMIs, insulin 
resistance, and obesity 
South Asian Highest reported 
prevalence of PCO 
morphology in British 
immigrants (52%)  
Significantly higher rates of IR 
compared to White women 
Middle Eastern Less PCO morphology 
than White women  
Better cardiovascular profile than 
White women, but increased risk for 
hyperandrogenism, type II diabetes, 
and metabolic syndrome 
Maori/Pacific 
Islander 
N/A Higher levels of androgens, 
triglycerides, fasting insulin, LDL 
cholesterol, and blood pressure; 
hirsutism comparable to White women; 
obesity comparable to all groups 
 
The difference in PCOS prevalence between White and Black women was noted 
to be insignificant, with 4.7% and 3.4% prevalence respectively in a study done on 
women in the southeastern US. (Knochenhauer et al., 1998). Ladson et al also found that 
the associated reproductive profiles and degree of hirsutism did not significantly differ 
between White and Black women with PCOS, but contrary to previous data indicating 
poorer metabolic profiles in Black women due to increased BMI, glucose levels, 
hypertension, and insulin resistance, this study suggested a more favorable phenotype 
among Black women with PCOS (Ladson et al., 2011; Legro et al., 2006). In general, 
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non-Hispanic Black women were found to have a milder PCOS phenotype compared to 
both non-Hispanic White and Hispanic women (Engmann et al., 2017). This may be a 
factor in why the diagnostic rates for Black women are slightly lower than they are for 
White women (Lo et al., 2006).  
 Hispanic women, on the other hand, are considered to have a more severe 
phenotype than White women. Dunaif et al (1993) found that Caribbean-Hispanic women 
have nearly twice the prevalence for PCOS compared to both White and Black women, 
which may be attributed to and exacerbated by a higher degree of insulin resistance found 
in that population, with the insulin resistance possibly unmasking a genetic susceptibility 
to PCOS in these women. Similar to the Caribbean-Hispanic population, Mexican 
Americans in Texas were also noted to have a significant association between PCOS and 
a considerably higher degree of insulin resistance compared to White women, which is 
expected based on the higher rates of IR, hyperinsulinemia, type II diabetes, and obesity 
among Mexican Americans, though not as high as noted among the Caribbean-Hispanic 
population (Kauffman, Baker, DiMarino, Gimpel, & Castracane, 2002; Welt et al., 2006). 
Kauffman et al. (2002) draw an epidemiological connection between this data and the 
high prevalence among Pima Indians, Micronesians, Puerto Ricans, and Cubans, 
suggesting a genetic role in the pronounced manifestation of these phenotypic markers of 
PCOS. Hispanic women were also noted to have the highest prevalence of PCO 
morphology in one or both ovaries, compared to White or Black women, with additional 
support for the most severe PCOS phenotype in terms of insulin resistance as well as 
hyperandrogenemia, hyperinsulinemia, systolic hypertension, and hyperglycemia 
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(Engmann et al., 2017). Hispanics with PCOS were also noted to be more hirsute than 
those without PCOS (Legro et al., 2006). The pronounced symptomatic presentation in 
Hispanics might contribute to the higher rates of PCOS diagnosis among this ethnic 
group (Lo et al., 2006).  
 Among East Asians, the prevalence is noted to be lower, as exemplified by a 
study in southern China that found it to be 2.2%, but it is uncertain whether this is due to 
intrinsic biology, lifestyle factors, obesity rates, or the diagnostic criteria used (Chen et 
al., 2008). Asians are noted to have lower BMIs and testosterone levels, as well the 
lowest rates of insulin resistance and obesity (Legro et al., 2006; Lo et al., 2006; 
Glintborg, Mumm, Hougaard, Ravn, & Andersen, 2010).  
 South Asian women in particular had a pronounced prevalence of PCOS and the 
PCOS phenotype, with the severity of the symptoms present in younger South Asian 
women matching those in older White women (Williamson, Gunn, Johnson, & Milsom, 
2001; Wijeyaratne, Balen, Barth, & Belchetz, 2002). Asian Indian women had 
significantly higher rate of insulin resistance in the population, with higher insulin 
concentrations and sensitivity to a glucose load, compared to White counterparts 
(Wijeyaratne et al., 2002). A study of South Asian British immigrants also showed that 
this population had the highest reported prevalence of PCO morphology at 52% 
(Wijeyaratne et al., 2002).  
 Middle Eastern women were found to have a lower prevalence of PCO 
morphology compared to White women, as well as a more favorable cardiovascular 
profile, but they also demonstrated an increased risk for hyperandrogenism, diabetes, and 
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metabolic syndrome (Glintborg et al., 2010). The Middle Eastern women with PCOS 
were also noted to be younger on average compared to White women. It is possible that 
since Middle Eastern women are less likely to use hormonal contraceptives, they have an 
earlier presentation of the PCOS phenotype (Glintborg et al., 2010).  
 Maori and Pacific Islander women were also found to have a fairly pronounced 
prevalence of PCOS phenotype, with elevated androgens, triglycerides, fasting insulin, 
LDL cholesterol, and blood pressure (Williamson et al., 2001). Like White/European 
women, they had a greater concern for the presentation of PCOS-associated hirsutism 
compared to other race/ethnicity groups. Like all other race/ethnicity groups, they also 
had significant prevalence of obesity in conjunction with the PCOS phenotype 
(Williamson et al., 2001).   
 The presentation of PCOS is also affected by age, as the primary markers for the 
disorder depend on factors that undergo significant change across the lifespan. Lo et al. 
(2006) notes that the highest prevalence for PCOS was within the 25-34 age group, with 
1 in 38 women having received a diagnosis, and an additional 1 in 20 women presenting 
with PCOS symptomatology (oligomenorrhea and hirsutism). The authors attributed this 
prevalence to the increased awareness of PCOS over the last few decades, leading to 
young women being more knowledgeable about the disorder. This young population was 
also more likely to be educated, lending to the increased awareness of potential health 
concerns (Lo et al., 2006). Additionally, since women in this particular age group are in 
their peak reproductive years, they may be more likely to seek clinical attention for 
menstrual dysfunction, androgen excess, or infertility (Lo et al., 2006). Finally, new 
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presentation of PCOS symptoms might be less likely or less concerning above the age of 
35, leading to fewer people in that age group seeking clinical evaluation (Lo et al., 2006) 
 Uncertainty remains in regards to understanding of differences in PCOS across 
populations. Engmann & Legro (2013) attribute this gap in understanding to the high 
degree of variability present in the participant study populations, recruitment methods, 
and diagnostic criteria used, leading to imprecise comparisons in data. The differences 
that are found between different groups in a study population could also be attributed to 
many factors, whether they are due to genetic differences or environmental influences, 
such as culture, lifestyle, accessibility of care, or quality of healthcare received (Engmann 
& Legro, 2013). To continue to improve on the data available, Engmann & Legro (2013) 
recommend that large, comparative, population-based prospective studies are needed to 
minimize selection bias related to case studies, as well as potentially allow for the 
appropriate targeting of vulnerable populations to help with the treatment and prevention 
of long-term consequences related to PCOS, particularly metabolic disorders. Overall, the 
varying clinical prevalence and presentation of the PCOS phenotype across different 
race/ethnicity and age groups suggests the need for distinct preclinical markers to be used 
in evaluation (Engmann et al., 2017) 
Diagnosis of PCOS With Presence of Menstrual Irregularity 
 Menstrual irregularity, in the form of oligo- or amenorrhea, lasting more than a 
year post-menarche is suggestive of ovarian dysfunction (Livadas et al., 2011). Literature 
suggests that about 70-80% of patients diagnosed with PCOS present with clinically 
evident menstrual irregularity, while only 20% of PCOS women have eumenorrhea 
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(Azziz, 2006). Oligomenorrhea is one of the most common features of PCOS present 
from puberty (Livadas et al., 2011). Menstrual irregularity is associated with insulin 
resistance, and the elevated insulin levels trigger the theca cell layer to produce surplus 
androgens, exacerbating the hyperandrogenemia that disrupts follicular growth (Goodarzi 
et al., 2011). 
Drawing the connection between menstrual irregularity and PCOS is important 
due to the variety of medical problems associated with their concurrence. Due to its 
comorbidity with insulin resistance, the presence of menstrual irregularity also increases 
risk of type II diabetes, cardiovascular disease, coronary heart disease or other 
cardiovascular incidents by age 45, and metabolic syndrome, regardless of age of onset of 
the irregularity, compared to individuals with normal menstrual cycles (Goodarzi et al., 
2011; Livadas et al., 2011; Wang et al., 2011). The age of onset also did not appear to 
affect the severity of the PCOS phenotype later in life (Livadas et al., 2011). PCOS 
patients with irregular cycles are more likely to be obese, have a higher waist to hip ratio, 
and have poorer hormonal and metabolic profiles than those with normal cycles 
(Christodoulopoulou et al., 2016). A study on PCOS women in South Korea found that 
the abnormal metabolic phenotype (including high BMI, waist circumference, blood 
pressure, lipids, glucose, insulin, and testosterone, and low HDL) associated with PCOS 
presents in a gradient of severity, with milder metabolic disturbance coinciding with mild 
oligomenorrhea without PCOS and the most severe metabolic disturbance coinciding 
with severe oligomenorrhea with PCOS (Oh, Sung, & Lee, 2014). This gradient was also 
more pronounced in obese and overweight patients (Oh et al., 2014). Panidis et al. (2013) 
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also found that the more severe menstrual irregularities correlated with more severe 
presentations of IR, but women who had alternating regular cycles or polymenorrhea 
were noted to have no difference in IR prevalence, indicating that the type of menstrual 
abnormality might be useful in determining the severity of metabolic dysregulation. 
Menstrual irregularities from a young age are also predictive of reproductive issues, 
including PCOS, later on in life. A study using the Northern Finland Birth Cohort found 
that women who had menstrual irregularities at age 16 were more likely to have 
menstrual irregularity in the form of anovulation, PCOS, and/or infertility problems at 
age 26 than women who had normal cycles at age 16, even after adjusting for 
confounders (West et al., 2014). Irregular menstruation within the first two post-
menarchal years in girls who were obese, overweight, or had acanthosis nigricans was 
also seen to be associated with a higher prevalence of IR, PCOS, and metabolic syndrome 
(da Silva Bouzas et al., 2014). 
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SPECIFIC AIMS 
 
This thesis project seeks to determine the prevalence of PCOS diagnoses with self-
reported histories of menstrual irregularity in a diverse, multiethnic cohort, as established 
by the Ovulation and Menstruation Study at Boston University School of Medicine. 
Specifically, this paper aims to:  
1. Determine the likelihood of reporting a diagnosis of PCOS among women who 
self-report current or previous menstrual irregularity 
2. Determine the prevalence of menstrual irregularity by race/ethnicity and country 
of birth in a diverse, multiethnic cohort 
3. Determine the diagnosis of PCOS across categories of race/ethnicity, immigration 
status, education, and age in a diverse, multiethnic cohort 
Ultimately, this research seeks to understand what changes need to be considered in the 
evaluation of reproductive health, with particular regard to the individual menstrual cycle 
patterns in women of all demographic variations. The results of this study aim to offer 
insight that will help better recognize and treat PCOS, not only to be able to manage 
symptoms appropriately, but also target reproductive and general health concerns earlier 
on to facilitate better health outcomes. 
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METHODS 
 
The Ovulation and Menstruation (OM) Study 
 The Ovulation and Menstruation (OM) Study pilot at Boston University School of 
Medicine aims to address the deficiencies in pre-existing cohorts to contribute to the 
future study of PCOS, including the data used in this analysis. The OM Study utilizes a 
13-section electronic survey that asked participants questions regarding their ovulatory 
and menstrual cycles, general health history, and demographic information in order to 
understand the factors that promote ovulation and menstruation health across the lifespan, 
as well as factors that increase the risk for ovulation disorders such as PCOS. The dataset 
utilized for this study was gathered from patients recruited by multiple methods across 
multiple cities in the United States between August 9th, 2017 and October 24th, 2017. The 
survey was administered through the REDCap, a secure web application for building and 
managing online surveys and databases specifically targeted to support research studies 
and operations.  
 
Participant Recruitment  
 The inclusion criteria for the study was defined as women between the ages of 18-
45 who had menstrual periods and had no history of chemotherapy, radiation, or surgical 
menopause (i.e. hysterectomy, oophorectomy). They were not recruited with 
consideration of menstrual irregularity or PCOS diagnosis present. Participants were 
initially recruited from the OB/GYN clinics in the Doctor’s Office Building and Yawkey 
Clinic at Boston Medical Center, approached as they were in the waiting room prior to 
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their appointment. Recruitment later expanded to include dissemination of the study 
website link (with the link to the survey) via Facebook to reach the social networks of the 
research assistants, based in Massachusetts, Missouri, and California. Research assistants 
also did in-person recruitment at a local community Women’s Market in Jamaica Plains, 
Boston, MA. For in-person recruitment encounters, individuals were asked to first view 
an informational video about PCOS, specifically created for the OM Study, prior to 
completing a screener and then proceeding to the actual survey. Those who accessed the 
survey online through the study link were provided the video on the home page, and then 
directed to the screener and questionnaire. Individuals who were not able to complete the 
survey in their first sitting were sent follow-up emails through REDCap, through which 
they could access their survey using a provided code from the location they left off.  As 
compensation, participants were entered into a raffle for a $200 gift card, which was 
awarded at the end of the aforementioned time window. 
 
Study Population  
The recruitment methods used allowed the OM study pilot to attain geographic and age-
group diversity. Due to low power n values of the dataset’s original categories, the three 
categories for women identifying as Asian (East Asian, South Asian, and South-East 
Asian) were collapsed into one category, “Asian”. Additionally, the race categories of 
Middle Eastern and North African, Native Hawaiian or other Pacific Islander, and Native 
American or Alaskan Native were also underrepresented, with responders from the pilot 
exclusively falling under the “More than one race” category.  
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Measures 
 The data for the variables being assessed under this paper’s hypotheses are 
directly pulled from responses to the demographic, menstrual cycle, and polycystic ovary 
syndrome sections of the OM Study survey (found in survey Section I – Screener, 
Section IV – Baseline Questionnaire, Section VI – Menstrual Cycle, and Section IX – 
Polycystic Ovary Syndrome) (Appendix I).  
Determination of menstrual irregularity – Individuals were determined to have menstrual 
irregularity based on the responses provided to the questions related to menstrual cycles. 
An individual was considered to have an irregular menstrual period if they fell into at 
least one of the following parameters: 
• Delayed regulation of cycle of ≥3 years  
• Menstrual cycle length of <21 days OR >35 days 
• Number of menstrual periods in last year <10 OR >18   
Determination of PCOS – Individuals self-reported whether they had a diagnosis for 
PCOS. These individuals were represented separately in the analysis for an official 
diagnosis from a healthcare provider vs. a self-diagnosis.  
Determination of PCOS among women with menstrual irregularity – Participants who 
provided responses indicating self-reported periods of menstrual irregularity previously 
for 3+ months, currently, or any response following the previously mentioned criteria for 
menstrual irregularity were further categorized on whether they reported a clinician 
diagnosis, self-diagnosis, or no diagnosis for a cross-sectional analysis of these two 
variables. 
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A risk ratio was then calculated for each menstrual irregularity category, which 
was interpreted as a prevalence ratio for the diagnosis of PCOS. For this calculation, the 
separate categories of clinician and self-diagnoses were collapsed into one overarching 
PCOS diagnosis category. Both the risk ratios and their confidence intervals were hand-
calculated. The risk ratios were calculated by dividing the cumulative incidence of PCOS 
diagnoses among all people with menstrual irregularity by the cumulative incidence of 
PCOS diagnoses among all the people without menstrual irregularity. The confidence 
interval for the risk ratios were calculated using the equation 
, with RR representing the calculated risk ratio, z 
representing the z-score for a 95% confidence interval, n representing the number of 
participants with or without a menstrual irregularity, and x representing the total number 
of patients with a diagnosis for PCOS, with or without a menstrual irregularity. 
 It is important to note that in the OM Study survey, patients were not required to 
specify the temporal relationship between their menstrual irregularity and their diagnosis 
of PCOS. Additionally, their diagnoses were considered in isolation of any other potential 
symptoms that could have influenced the determination of their diagnosis, including PCO 
morphology, hirsutism, weight gain, and insulin resistance. Therefore, a cross-sectional 
analysis was performed using the available data, rather than any determination of the 
temporal relationship between menstrual irregularity and PCOS diagnosis. Consideration 
should be given for the various temporal possibilities of how participants reporting PCOS 
had reached their diagnosis, including the presentation of symptoms outside of menstrual 
irregularity. A few example possibilities for context are shown in Figure 2.   
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Figure 2. Example Timelines to PCOS Diagnosis. 
 
Figure 2. Timelines (a), (b), and (c) present hypothetical example timelines involving 
various contributing symptoms that could lead to a diagnosis of PCOS in participants. 
Timeline (a) has a menstrual irregularity presenting before biological hyperandrogenism 
is also noted in the patient, eventually leading to a diagnosis. Timeline (b) has signs of 
clinical hyperandrogenism (acne and hirsutism) presenting before a menstrual 
irregularity is noted and PCOS is diagnosed. Timeline (c) does not even involve a 
menstrual irregularity, with the diagnosis for PCOS coming after the evaluation of 
hirsutism and PCO morphology in the patient. These hypothetical scenarios demonstrate 
the potential variability in symptom presentation that could have led to a participant’s 
diagnosis, independent of whether or not they specifically had menstrual irregularity.  
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RESULTS 
 Of the 248 total participants in the OM Study survey, 236 provided answers for 
questions from Section VI: Menstrual Cycle and 225 provided answers for questions 
from Section IX: Polycystic Ovary Syndrome. The discrepancy in numbers of 
participants is attributed to the fact that participants were not required to provide answers 
for all questions, resulting in skip patterns, and that not all participants that contribute to 
the pilot dataset finished the entirety of the questionnaire. This also explains the varied N 
value from question to question in each section.  
 Participants were predominantly White (64.9%), with the majority being 
recruited from the Boston Women’s Market. Black, Hispanic, and mixed-race 
representation were about equal, and Asian participation was markedly low, even after 
combining the otherwise-separated groups of South, Southeast, and East Asian for a 
combined percentage of 4.2% of the study population. The majority of participants were 
born in the US (80.9%). The study population was primarily made up of young, educated 
women, with 44% being under the age of 24 and an additional 39% being between 25 and 
34, and a total of 77.5% of the women holding a 4-year college degree (37.3%) or higher 
(40.2%). (Table 2). 
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Table 2. OM Study Population – Baseline Demographic Characteristics of Interest. 
OM Study population descriptive data, including age, race, country of birth, and 
education level.  
Characteristics Participants 
n % 
Total number of participants 248 100% 
Mean age (years)  27.6  
18-24 109 43.9% 
25-34 37 39.1% 
35-45 36 14.5% 
45+  6 2.4% 
Race    
 White  159 64.9% 
Hispanic, Latina, or Spanish Origin  22 9.0% 
Black/African American  30 12.2% 
Asian 11 4.2% 
More than one race  23 9.4% 
Country of Birth     
Born in the US 199 80.9% 
Born outside of the US 47 19.1% 
Education    
Some high school, but did not 
graduate 
1 0.4% 
High school graduate or GED 18 7.4% 
Some college or 2-year degree 36 14.8% 
4-year college graduate 91 37.3% 
More than 4-year college degree 98 40.2% 
 
The data from the study population was primarily used to perform a cross-
sectional analysis between having a menstrual irregularity and having a diagnosis for 
PCOS, whether given by a clinician or determined on one’s own, as self-reported in the 
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OM Study survey. Based on an analysis of the data, a diagnosis for PCOS appeared to be 
more common when a menstrual irregularity was also self-reported, whether determined 
by a clinician or the participants themselves. The most commonly reported characteristic 
present in conjunction with a PCOS diagnosis was having a history of a previous 
menstrual irregularity for 3 or more months, with 93.9% of the official diagnoses and 
75.0% of the self-diagnoses reporting this pattern. The prevalence ratio indicated a 4.4-
fold chance that the individual with a menstrual irregularity would have a diagnosis for 
PCOS, compared to individuals without a menstrual irregularity. They were followed 
closely by the presence of current menstrual irregularity and delayed or lack of menstrual 
regulation 3+ years after menarche. The least likely menstrual irregularity to have a 
coinciding diagnosis of PCOS was an irregular number of menstrual periods per year, 
with a prevalence ratio of 2.1. There was not a notable difference between individuals 
with a clinician diagnosis and those with a self-diagnosis in these two categories. There 
was a higher prevalence of menstrual irregularity compared to menstrual regularity in all 
assessed menstrual cycle categories, with the exception of delayed regulation after 
menarche. (Table 3).  
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Table 3. Presence of a Diagnosis for PCOS with Menstrual Irregularity. Given the 
presence of a menstrual irregularity (defined by delayed regulation of menstrual cycle 
after menarche, previous menstrual irregularity for 3+ months, current menstrual 
irregularity given previous menstrual irregularity, irregular menstrual cycle length, 
and/or irregular number of annual periods), the prevalence of PCOS diagnosis was 
determined, based on criteria used in Table 4a -g. Risk ratios were then calculated for 
each individual type of menstrual irregularity using the combined total diagnoses for 
PCOS, and were interpreted for this study as prevalence ratios. 
 
 
 
 
 
 Diagnosis of PCOS Non-
PCOS  
Prevalence 
Ratio 
Confidence 
Interval Clinician  Self Total 
Delayed 
regulation of 
menstrual cycle 
after menarche  
17/32 
(53.1%) 
10/16 
(62.5%)  
27/48 
(56.2%) 
39/175 
(18.2%) 
3.1 (0.64, 1.62) 
Previous 
menstrual 
irregularity for  
3+ months  
31/33 
(93.9%) 
12/16 
(75.0%) 
43/49 
(87.8%) 
96/176  
(54.5%) 
4.4 (0.67, 2.29) 
Current 
menstrual 
irregularity 
after previous 
irregularity  
22/33 
(66.7%) 
8/16 
(50.0%) 
30/49 
(61.2%) 
42/175 
(24.0%) 
3.3 (1.07, 1.33)  
Irregular 
menstrual cycle 
length  
9/30  
(30.0%) 
3/16  
(18.8%) 
12/46 
(26.1%) 
12/166  
(7.2%) 
2.8 (0.53, 1.53) 
Irregular 
menstrual 
periods in  
previous year  
13/30  
(43.3%) 
6/15  
(40.0%) 
19/45 
(42.2%) 
32/151  
(21.2%) 
2.1 (0.95, 1.95) 
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The individual variables of menstrual irregularity and PCOS diagnosis were also 
examined individually across demographics factors. Out of all the presumed or known 
causes for menstrual irregularity that were asked in the OM study survey, stress (39.3%) 
and PCOS (20.7%) were the most commonly self-reported (Table 4).  
Table 4. Self-reported causes for menstrual irregularities for greater than 3 months. 
Cause for Menstrual Irregularity 
(N=145) 
Participants 
n % 
Stress  57/145 39.3% 
Polycystic Ovary Syndrome  30/145 20.7% 
Hormonal Abnormality  28/145 11.8% 
Too much exercise/not enough 
to eat  
26/145 10.9% 
Overweight/Obese  12/145 5.0% 
Pregnancy/Breastfeeding  10/145 4.2% 
Other  31/145 13.0% 
Don’t Know  42/145 17.6% 
 
When looking at menstrual irregularity across race/ethnicity categories, data indicated 
similar rates of menstrual irregularity, ranging from 57.1% in Black/African-Americans 
and 72.7% in Asians prior to the time of survey completion (“previous menstrual 
irregularity”), to 27.2% in Asians and 39.2% in Black/African-Americans at the time of 
survey completion (“current menstrual irregularity”) (Table 5c, 5d). Similar trends also 
presented between participants born in the US vs. immigrants born elsewhere (62.8% vs. 
54.7% previously, and 31.0% vs 35.7% currently) (Table 5c, 5d). There were no 
particularly notable trends seen in the time to regulation of the menstrual period across 
race/ethnicity groups or the length of the menstrual cycle (Table 5b, 5f). All groups also 
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remained close to the mean number of menstrual periods per year (10.2) (Table 5g). Age 
of menarche did show some variation, with a higher proportion of Black (17.7%) and 
Hispanic (20.0%) women achieving menarche at under the age of 11 compared to White 
(8.5%), Asian (10.0%), and mixed race (4.3%) women (Table 5a).   This was also true of 
Black women achieving menarche at or above the age of 16 (7.1%), compared to women 
of other races (White – 3.8%, Hispanic – 3.2%, Asian – 5.2, mixed-race – 0.0%) (Table 
5a).   
 	
Table 5a. Age of menarche. Participants reported the ages at which they achieved menarche (the age at which they had their 
first menstrual period), presented here by race and country of origin.   
 	 
 
 
 
 
 
 
 
Age at 
menarche 
Total 
Participants 
(N = 233) 
White 
(N = 152) 
Hispanic 
(N = 20) 
Black 
(N = 28) 
Asian 
(N = 10) 
More than one 
race 
(N = 23) 
US-born 
(N = 190) 
Non-US-born 
(N = 43) 
≤7 years 1/233  
(0.4%)  
0/152 
(0.0%)  
0/20 
(0.0%) 
1/28 
(3.5%) 
0/10 
(0.0%) 
0/23 
(0.0%) 
0/190 
(0.0%) 
1/43 
(2.3%) 
8-10 
years 
23/233  
(9.8%)  
13/152 
(8.5%)  
4/20  
(20.0%) 
4/28  
(14.2%)  
1/10 
(10.0%) 
1/23 
(4.3%) 
18/190 
(9.4%) 
5/43  
(11.6%) 
11 years 46/233  
(19.7%)  
27/152 
(17.7%) 
5/20 
(25.0%) 
6/28 
(21.4%) 
1/10 
(10.0%) 
7/23 
(30.4%) 
36/190 
(18.9%) 
10/43 
(23.2%) 
12 years 65/233  
(27.8%) 
46/152 
(30.2%) 
5/20 
(25.0%) 
3/28 
(10.7%) 
5/10 
(50.0%) 
6/23 
(26.1%) 
55/190 
(28.9%) 
10/43 
(23.2%) 
13 years 52/233  
(22.3%) 
35/152 
(23.0%) 
2/20 
(10.0%) 
6/28 
(21.4%) 
2/10 
(20.0%) 
7/23 
(30.4%) 
45/190 
(23.6%) 
7/43 
(16.2%) 
14 years 24/233  
(10.3%)  
17/152 
(11.1%) 
3/20  
(15.0%) 
3/28 
(10.7%) 
0/10 
(0.0%) 
1/23 
(4.3%) 
20/190 
(10.5%) 
4/43 
(9.3%) 
15 years  13/233  
(5.5%)  
9/152 
(5.9%) 
0/20 
(0.0%) 
3/28 
(10.7%) 
0/10 
(0.0%) 
1/23 
(4.3%) 
9/190 
(4.7%) 
4/43 
(9.3%) 
≥16 years 9/233  
(3.8%)  
5/152 
(3.2%) 
1/20 
(5.0%) 
2/28 
(7.1%)  
1/10 
(10.0%) 
0/23 
(0.0%) 
7/190 
(3.6%)  
2/43 
(4.6%) 
32 
 	
Figure 3a. Graph of age of menarche by race/ethnicity. 
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Figure 3b. Graph of age of menarche by country of birth. 
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Table 5b. Time to menstrual cycle regulation after menarche. Participants reported how long it took for their menstrual cycle 
to achieve regularity after menarche, presented here by race and country of origin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time to 
regulation of 
menstrual 
cycle after 
menarche 
Total 
Participants 
(N = 236) 
White 
(N = 155) 
Hispanic 
(N = 19) 
Black  
(N = 28) 
Asian 
(N = 11) 
More than 
one race 
(N = 23) 
US-born 
(N = 193) 
Non-US-
born 
(N = 43) 
<1 year  123/236 
(52.1%) 
76/155 
(49.0%) 
10/19 
(52.6%) 
19/28 
(67.8%) 
6/11 
(54.5%) 
12/23 
(52.1%) 
96/193 
(49.7%) 
27/43 
(62.7%) 
1-2 years 45/236 
(19.0%) 
34/155 
(21.9%) 
4/19 
(21.0%) 
3/28 
(10.7%) 
0/11 
(0.0%) 
4/23 
(17.3%) 
38/193 
(19.6%) 
7/43 
(16.2%) 
3-4 years 12/236 
(5.0%) 
7/155 
(4.5%) 
1/19 
(5.2%) 
1/28 
(3.5%) 
0/11 
(0.0%) 
3/23 
(13.0%) 
9/193 
(4.6%) 
3/43 
(6.9%) 
≥5 years 14/236 
(5.9%) 
10/155 
(6.4%) 
0/19 
(0.0%) 
1/28 
(3.5%) 
2/11 
(18.1%)  
1/23 
(4.3%) 
14/193 
(7.2%) 
0/43 
(0.0%) 
Never 42/236 
(17.7%) 
28/155 
(18.0%) 
4/19 
(21.0%) 
4/28 
(14.2%) 
3/11 
(27.2%)  
3/23 
(13.0%) 
36/193 
(18.6%) 
6/43 
(13.9%) 
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Figure 4a. Graph of time to menstrual cycle regulation by race/ethnicity 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
<1	year 1-2	years 3-4	years >5	years Never
%	Part
icipant
s
Time	to	Regulation	(years)
Time	to	Menstrual	Cycle	Regulation	by	Race/Ethnicity
White Hispanic Black Asian Mixed
36 
 	
Figure 4b. Graph of time to menstrual cycle regulation by country of birth.  
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Table 5c. Previous menstrual irregularity for >3 months. Participants reported whether they experienced menstrual 
irregularity for a time period of 3 months of greater, presented here by race and country of origin. This data includes the 
individuals who indicated that their menstrual cycle never became regular after menarche, as indicated in Table 4b. 
 
Table 5d. Current menstrual irregularity after previous menstrual irregularity. Participants reported whether they were 
currently experiencing menstrual irregularity, presented here by race and country of origin. The associated survey question 
was only asked of the individuals who reported a previous menstrual irregularity of 3 months or greater, as indicated in Table 
4c. This data also includes participants who indicated that their menstrual cycle never became regular after menarche, as 
indicated in Table 4b. 
 
 
 
 
 
 
 Total 
Participants 
(N = 236) 
White 
(N = 155) 
Hispanic 
(N = 19) 
Black 
(N = 28) 
Asian 
(N = 11) 
More than 
one race 
(N = 23) 
US-born 
(N = 194) 
Non-US-
born 
(N = 42) 
Previous 
menstrual 
irregularity for 
>3 months 
(N = 236)  
145/236 
(61.4%) 
94/155 
(60.6%) 
11/19 
(57.8%) 
16/28 
(57.1%) 
8/11 
(72.7%) 
16/23 
(69.5%) 
122/194 
(62.8%) 
23/42 
(54.7%) 
 Total 
Participants 
(N = 235) 
White 
(N = 154) 
Hispanic 
(N = 19) 
Black 
(N = 28) 
Asian 
(N = 11) 
More than 
one race 
(N = 23) 
US-born 
(N = 190) 
Non-US-
born 
(N = 43) 
Current 
menstrual 
irregularity  
(N = 235) 
75/235 
(31.9%) 
46/154 
(29.8%) 
7/19 
(36.8%) 
11/28 
(39.2%) 
3/11 
(27.2%) 
8/23 
(34.7%)  
60/193  
(31.0%) 
15/42 
(35.7%) 
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Table 5e. Duration of menstrual flow. Participants reported the average duration of their menstrual period, reported as 
number of days of bleeding during a given period. 
  
 
 
 
 
 
 
 
 
 
 
Menstrual 
flow 
duration 
Total 
Participants 
(N = 235) 
White 
(N = 154) 
Hispanic 
(N = 19) 
Black 
(N = 28) 
Asian 
(N = 11) 
More than 
one race 
(N = 23) 
US-born 
(N = 193) 
Non-US-
born 
(N = 42) 
<3 days  14/235 
(5.9%) 
10/154 
(6.4%) 
1/19 
(5.2%) 
1/28 
(3.5%) 
0/11 
(0.0%) 
2/23 
(8.6%) 
11/193 
(5.6%) 
3/42 
(7.1%) 
3 days 33/235 
(14.0%) 
19/154 
(12.3%) 
4/19 
(21.0%) 
5/28 
(17.8%) 
1/11 
(9.0%) 
4/23 
(17.3%) 
27/193 
(13.9%) 
6/42 
(14.2%) 
4 days  59/235 
(25.1%) 
42/154 
(27.2%) 
4/19 
(21.0%) 
6/28 
(21.4%) 
4/11 
(36.3%) 
3/23 
(13.0%) 
51/193 
(26.4%) 
8/42 
(19.0%) 
5 days 68/235 
(28.9%) 
50/154 
(32.4%) 
3/19 
(15.7%) 
7/28 
(25.0%) 
2/11 
(18.1%) 
6/23 
(26.0%) 
56/193 
(29.0%) 
12/42 
(28.5%) 
6 days  38/235 
(28.9%) 
25/154 
(16.2%) 
3/19 
(15.7%) 
4/28 
(14.2%) 
2/11 
(18.1%) 
4/23 
(17.3%) 
31/193 
(16.0%) 
7/42 
(16.6%) 
7 days 17/235 
(7.2%) 
6/154 
(3.8%) 
4/19 
(21.0%) 
4/28 
(14.2%) 
1/11 
(9.0%) 
2/23 
(8.6%) 
13/193 
(6.7%) 
4/42 
(9.5%) 
>8 days  6/235 
(2.5%) 
2/154 
(1.2%) 
0/19 
(0.0%) 
1/28 
(3.5%) 
1/11 
(9.0%) 
2/23 
(8.6%) 
4/193 
(2.0%) 
2/42 
(4.7%)  
39 
 	
Figure 5a. Graph of duration of menstrual flow by race/ethnicity.  
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Figure 5b. Graph of duration of menstrual flow by country of birth.  
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Table 5f. Length of menstrual cycle. Participants reported the length of their menstrual cycle, defined as the number of days 
from the first day of a menstrual period to the first day of the next menstrual period, presented here by race and country of 
origin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Menstrual 
cycle length  
Total 
Participants 
(N = 222) 
White 
(N = 145) 
Hispanic 
(N = 18) 
Black 
(N = 27) 
Asian 
(N = 11) 
More than 
one race 
(N = 21) 
US-born 
(N = 182) 
Non-US-
born 
(N = 40) 
21-25 days  33/222 
(14.8%) 
19/145 
(13.1%) 
2/18 
(11.1%) 
3/27 
(11.1%) 
4/11 
(36.3%) 
5/21 
(23.8%) 
24/182 
(13.1%) 
9/40 
(22.5%) 
26-29 days 102/222 
(45.9%) 
70/145 
(48.2%) 
8/18 
(44.4%) 
12/27 
(44.4%) 
4/11 
(36.3%) 
8/21 
(38.0%) 
85/182 
(46.7%) 
17/40 
(42.5%) 
30-35 days 62/222 
(27.8%) 
42/145 
(28.9%) 
6/18 
(33.2%) 
8/27 
(29.6%) 
1/11 
(9.0%) 
5/21 
(23.7%) 
49/182 
(26.8%) 
13/40 
(32.5%) 
>35 days  25/222 
(11.2%) 
14/145 
(9.6%) 
2/18 
(11.1%) 
4/27 
(14.8%) 
2/11 
(18.1%) 
3/21 
(14.2%) 
24/182 
(13.1%) 
1/40 
(2.5%) 
42 
 	
Figure 6a. Graph of length of menstrual cycle by race/ethnicity.  
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Figure 6b. Graph of length of menstrual cycle by country of birth. 
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Table 5g. Mean annual menstrual periods. Participants reported the number of menstrual periods they had in the last 12 
months, presented here as a sample mean by race and country of origin. 
 
 
 
 Total 
Participants 
(N = 206) 
White 
(N = 139) 
Hispanic 
(N = 15) 
Black  
(N = 22) 
Asian 
(N = 11) 
More than 
one race 
(N = 19) 
US-born 
(N = 169) 
Non-US-
born 
(N = 37) 
Mean 
number of 
menstrual 
periods last 
year 
 
10.2 10.1 8.9 11.0 11.6 10.1 10.1 10.4 
45 
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Among all individuals diagnosed with PCOS, the proportions of Hispanic 
(35.2%), Black (28.0%), and Asian (30.0%) individuals holding a clinician diagnosis 
were higher compared to those who were White (9.3%) or mixed-race (13.0%) within 
their respective race/ethnicity group. On the other hand, there was a noticeable difference 
in the distribution of self-diagnoses for PCOS, with White individuals having a similar 
prevalence to clinician diagnoses compared to the other race categories, which only had 1 
person each with a self-diagnosis, if any. US-born individuals were also far more likely to 
have a self-diagnosis than immigrants (7.9% vs. 2.7%). With greater levels of education, 
the prevalence of both self-reported official and self-diagnoses increased. Participants 
were most likely to receive an official diagnosis for PCOS between the ages of 18-24 
(62.0%), but self-diagnoses were self-reported to be more even across age categories. 
Finally, individuals were more likely to have an official (84.8%) or self-diagnosis 
(81.2%) below the age of 34 than those above 34. (Table 6) 
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 Clinician diagnosis  
N = 33 
Self-diagnosis 
N = 16  
Non-PCOS 
N = 176 
Race     
White 14 (9.3%)  13 (8.6%)  123 (82.0%) 
Hispanic, Latina, or 
Spanish Origin  
6 (35.2%)  1 (5.8%)  10 (58.8%)  
Black or African 
American  
7 (28.0%)  0 (0.0%)  18 (72.0%) 
Asian  3 (30.0%) 1 (10.0%)  6 (60.0%)  
More than 1 
race/ethnicity 
3 (13.0%)  1 (4.3%)  19 (82.6%)  
Country of Birth    
      US born 25 (13.2%)  15 (7.9%) 149 (78.8%) 
      Outside of US 8 (22.2%)  1 (2.7%)  27 (75.0%) 
Education (% of 
diagnostic group)  
   
High school 
graduate, GED, or 
less 
4 (12.1%)  1 (6.2%)  10 (5.7%)  
Some college or 2-
year degree 
5 (15.1%)  1 (6.2%)  27 (15.4%)  
4-year college 
graduate 
10 (30.3%)  5 (31.2%)  70 (40.0%)  
More than 4-year 
college degree 
14 (42.4%)  9 (56.2%)  68 (38.8%)  
Age at Diagnosis (% 
of diagnostic 
group)  
   
<18 3 (10.3%%) 3 (25.0%)   
18-24 18 (62.0%) 4 (33.3%)   
25-34 6 (20.6%) 4 (33.3%)   
35-45 2 (6.8%)  1 (8.3%)   
Current Age (% of 
diagnostic group)  
   
18-24 7 (21.2%) 7 (43.7%)  89 (50.5%)  
25-34 21 (63.6%)  6 (37.5%)  64 (36.3%)  
35-45 5 (15.1%)  3 (18.7%)  20 (11.3%)  
45+  0 (0.0%)  0 (0.0%)  3 (1.7%)  
Table 6. Demographic Distribution of PCOS Diagnoses in the OM Study Population.  	
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DISCUSSION 
 The association between menstrual irregularity and polycystic ovary syndrome is 
one that is well-established – irregular menstruation even remains a predominant criterion 
in establishing a diagnosis for PCOS (The Rotterdam ESHRE/ASRM-sponsored PCOS 
consensus workshop group, 2004). Nevertheless, actually receiving a medical evaluation 
or a diagnosis for PCOS from a clinician based on menstrual irregularity or 
understanding that one’s menstrual irregularity might be associated with PCOS is not as 
much of a guarantee. Furthermore, women have consistently reported that they have been 
unsatisfied with their care in the evaluation of PCOS-related symptoms, failure to obtain 
a diagnosis of PCOS, and lack of guidance regarding their symptoms (Crete & 
Adamshick, 2011; Gibson-Helm et al., 2017). This paper evaluated the prevalence of 
menstrual irregularity and clinician and self-diagnoses of PCOS in a diverse cohort of 
women. Specifically, the paper sought to examine the correlation between the 
presentation of a menstrual irregularity and a diagnosis for PCOS, while also accounting 
for the fact that these variables might be modulated by demographic factors, including 
age, race/ethnicity, country of birth, and education.  
 
Menstrual Irregularity and PCOS 
 The primary goal of this study was to examine the concurrence of menstrual 
irregularities and PCOS diagnosis. In the analysis of the pilot cohort data, it was noted 
that a diagnosis for PCOS was far more common among those participants who had a 
menstrual irregularity than those who didn’t (Table 3). In particular, those who had 
  49 
reported either a previous or current unspecified menstrual irregularity lasting 3 months 
or longer had a substantially high prevalence of PCOS diagnoses. While this is expected 
in accordance with oligo- or anovulation being part of the criteria for PCOS diagnosis, it 
also potentially points to some of the less obvious and perhaps less tracked menstrual 
abnormalities that could serve as useful additional indicators towards a diagnosis for 
PCOS. For example, while delayed regulation after menarche is to be expected in 
adolescent girls, Livadas et al (2011) notes that a lack of menstrual regulation after even 
just 1 year post-menarche could be an indication of ovarian dysfunction, and could 
potentially indicate reproductive problems in the future, such as PCOS. Panidis et al 
(2013) further adds that the type of menstrual abnormality might be useful in 
understanding the severity of the resulting PCOS phenotype. Alternatively, it also 
indicates that even the types of menstrual irregularity most commonly associated with a 
diagnosis for PCOS (in this case, having a menstrual irregularity for 3+ months) still did 
not necessarily lead to all individuals in the category receiving a diagnosis for PCOS. 
This could indicate a potential red flag that clinicians could be made more aware of in 
their evaluation of a patient’s reproductive function and possible risk for PCOS.  
 
Menstrual Irregularity and Demographics  
 Data regarding menstrual cycle characteristics were compared across the 
demographic categories of race/ethnicity and immigration status. To assess for patterns in 
the menstrual cycle and check for regularity vs. irregularity, multiple factors were 
assessed, including the age of menarche, self-reported irregularity in the menstrual cycle 
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for over 3 months either previously or currently, the average duration of the menstrual 
flow, the average length of the menstrual cycle, and the number of periods per year. 
Based on the data collected, there were no noteworthy observations or differences in the 
presentation of the menstrual cycle across race/ethnicity groups or in those born in the US 
vs. outside of the US. This is somewhat in line with the current literature that 
acknowledges conflicting or no differences in the menstrual cycle across race/ethnicity.  
 
PCOS and Demographics  
 When considering the diagnosis of PCOS across demographic categories, this 
time also including age and education level in the breakdown of the data, there was a 
clear difference drawn between various groups. Among race/ethnic categories, there were 
a greater percentage of White women with a diagnosis, whether official or self, than 
participants in other categories. Furthermore, while there was no difference between the 
number of official vs. self-diagnoses among White women, there were noticeably fewer 
non-White women with self-diagnoses compared to official diagnoses for PCOS. This 
could potentially indicate a gap in awareness of this condition among certain groups. 
There is also an increased prevalence of diagnosis among younger and more educated, 
which while expected based on the current literature, still indicates the importance of 
educating women about PCOS and its associated symptoms.  
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Strengths, Limitations and Future Considerations  
This study benefits from deriving data from a large pilot cohort representing a 
diverse group of women of a broad age range and multiple ethnicities. They were 
recruited from various places by various methods in order to further increase the diversity 
of the cohort. Nevertheless, the results and conclusions discussed in this paper are 
certainly subject to limitations that must be considered. Due to the study population 
coming from a pilot cohort, many of the limitations were associated with the construction 
of the cohort. Despite the variety of methods used for recruitment in an attempt to 
increase the diversity of the cohort, the study population was still primarily a convenience 
sample that was predominantly White (64.9%), with comparatively small numbers of 
individuals scattered across the other groups. As a result, accurate comparisons were 
difficult to make due to the low power N of the non-White demographic groups, which 
falls into the weakness highlighted in the literature (Engmann & Legro, 2013). However, 
as mentioned previously, this is still more diverse than other PCOS cohorts, which 
primarily involved results from White women being compared to women of one or two 
other ethnicities at a time. Additionally, the recruitment of the participants may have been 
biased based on the source of recruitment, with more Hispanic and Black/African-
American individuals having been recruited out of the clinics at Boston Medical Center. 
This could have skewed the data for these demographics to be more likely to have PCOS 
or menstrual problems for which they would have presented to the clinic in the first place. 
On the other hand, more White participants and participants from higher education levels 
came from places of voluntary interest rather than in-person solicitation, which may have 
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indicated a personal or academic interest in the subject. Another limitation of the study 
was that it depended on participants self-reporting the presence of menstrual irregularity 
and their diagnosis of PCOS, without any form of medical record validation, leading to 
uncertainty regarding the accuracy of the data.  
Future directions would be to further expand the scope of the study population to 
make more valid assessments of PCOS diagnostic rates across demographic categories, 
particularly race/ethnicity. Increasing the number of individuals within each category 
would allow for a higher power in the data analysis and provide a better understanding of 
the true discrepancies present in recognizing and diagnosing PCOS based on criteria such 
as menstrual irregularity between different groups. Based on our data, it would be 
possible to more specifically target communities in need of more evaluation for PCOS, 
and better acknowledge the complexity of their symptom presentation and address 
treatment methods appropriately. Another potentially beneficial avenue of investigation 
would be incorporating medical record validation into the study and specifically focusing 
on the individuals who self-reported menstrual irregularity but did not have a diagnosis 
for PCOS. Further exploration of this subset of participants could provide valuable 
insight into alternate etiologies of menstrual irregularity or less understood presentations 
of PCOS that go underdiagnosed.   
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APPENDIX 
Questionnaire from Ovulation and Menstruation (OM) Study Pilot Survey 
 
Demographic Information 
 
Section I: Screener  1. How old are you now? 
________ (If age <18 then END OF SCREENER) 
Section IV: Baseline Questionnaire 1. Were you born in the United States of America? 
a. Yes 
b. No   à SKIP to #country 
4. Which categories describe you? Select all that apply. You may select more than 
one group. #raceethnic 
a. White  
For example, German Irish, English, Italian 
b. Hispanic, Latina, or Spanish Origin  
For example, Mexican, Mexican American, Puerto Rican, Cuban, 
Salvadoran, Dominican, Colombian, etc 
c. Black or African American 
For example, African American, Jamaican, Haitian, Nigerian, Ethiopian, 
Somali, etc. 
d. East Asian  
For example, Chinese, Japanese, Korean, Mongolian, Taiwanese, etc. 
e. Southeast Asian  
For example, Burmese, Cambodia, Hmong, Indonesian, Laotian, 
Malaysian, Filipino, Thai, Vietnamese, etc. 
f. South Asian  
For example Asian Indian, Bangladeshi, Bhutanese, Maldivian, Nepalese, 
Pakistani, Sri Lankan, etc.  
g. American Indian or Alaskan Native 
For example, Navajo Nation, Blackfeet Tribe, Mayan, Aztec, Native 
Village of Barrow Inupiat Traditional Government, Nome Eskimo 
Community, etc. 
h. Middle Eastern or North African 
For example, Lebanese, Iranian, Egyptian, Syrian, Moroccan, Algerian, 
etc. 
i. Native Hawaiian or Other Pacific Islander 
For example, Native Hawaiian, Samoan, Chamorro, Tongan, Fijian, 
Marshallese, etc. 
j. Some other race, ethnicity, or origin. 
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5. What is the highest level of education that you have completed? 
a. 8th grade or less 
b. Some high school, but did not graduate 
c. High school graduate or GED 
d. Some college or 2-year degree 
e. 4-year college graduate 
f. More than 4-year college degree 
 
 
Menstrual Cycle Questions 
 
Section VI: Menstrual Cycle  
1. At what age did you have your first menstrual period? 
a. 7 years old or younger  
b. 8 - 10 years old 
c. 11years old 
d. 12 years old 
e. 13 years old 
f. 14 years old 
g. 15 years old 
h. 16 years old or older 
i. Don’t remember  
 
2. Sometimes when a woman first gets her period, it’s not on a regular schedule and 
she may go months between periods. Thinking back to when you first got your 
period, how long did it take for your menstrual periods to become regular? 
#firstregularperiod 
a. My periods became regular in less than 1 year 
b. It took 1-2 years before my periods became regular 
c. It took 3-4 years before my periods became regular 
d. It took 5 or more years before my periods became regular 
e. My periods never became regular à SKIP to #whyirregular 
4.  Has there ever been a time when your menstrual period was NOT regular or 
predictable for more than a 3 month window of time? 
a. Yes   
b. No   à SKIP to #periodlength 
 
6. Why do you think your periods were irregular? (Check all that apply.) 
#whyirregular 
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a. Stress 
b. Polycystic ovary syndrome (PCOS) 
c. Hormonal abnormality 
d. Too much exercise and not eating enough 
e. Overweight/obesity 
f. Pregnancy/breastfeeding 
g. Other, please specify: 
h. Don’t know  
 
7. We are interested in whether your menstrual period is regular now – that means 
you can usually predict about when the next period will start. Would you say that 
your period is usually regular? 
a. Yes 
b. No  
 
8. Now we want to know about how long your period usually lasts.  Counting only 
the days when you were bleeding and not when you were spotting, in the last year 
about how many days did your period usually last? #periodlength 
a.  Less than 3 days 
b.  3 days 
c.  4 days 
d.  5 days 
e.  6 days 
f.   7 days 
g.   8 or more days 
 
9. Now we want to know about your menstrual cycle length – that is the number of 
days from the first day of one menstrual period to the first day of your next 
period. Normal menstrual cycle lengths range from 21 to 35 days. In the last year, 
about how long is your typical menstrual cycle length?  
a. _____ number of days (range check 21-35) à Skip to #MCnumber 
b. Don’t know  à Skip to #guessMC 
 
 
10. In the last 12 months, how many menstrual periods did you have? #MCnumber 
a. ______ (rangecheck 10-18) 
b. Don’t know 
Polycystic Ovary Syndrome Questions 
 
Section IX: Polycystic Ovary Syndrome 
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1. Polycystic Ovary Syndrome is a health condition involving irregular periods, 
excess testosterone, increased acne, body and facial hair, and many small cysts in 
the ovaries. Some women also experience hair loss on the scalp. Has a doctor ever 
diagnosed you with Polycystic Ovary Syndrome or PCOS? #PCOSdx 
a. Yes   à SKIP to #howdiagnosed 
b. No  
 
2. Do you think you might have PCOS? 
a. Yes   à SKIP to #whenthink 
b. No   à SKIP to #familypcos 
4. At what age were you first diagnosed with PCOS? a. _______________ b. Don’t remember 
7. When did you first think you may have PCOS? #whenthink 
c. Age in years______  
d. Don’t know 
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